Red Queen Therapeutics

Red Queen Therapeutics is a clinical-stage biotechnology company focused on developing novel antiviral therapies for a wide range of viral infections. Their innovative approach utilizes a stapled lipopeptide platform technology that blocks virus-cell fusion, a critical step in the infection process. This unique mechanism of action offers potential advantages over existing therapies, such as preventing viral entry, accelerating viral clearance, and working across entire viral families.

Red Queen's pipeline includes programs targeting SARS-CoV-2, RSV, hMPV, PIV, influenza, and herpes viruses. Their lead program, RQ-01, has shown promising results in Phase 1 trials for COVID-19, demonstrating safety and efficacy in accelerating viral clearance across multiple variants. Red Queen is committed to delivering accessible treatment options that can effectively combat viral infections and improve patient outcomes.

Red Queen Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel antiviral therapies to combat a wide range of viral infections, including influenzas, coronaviruses, and emerging pathogens. Their mission is to provide accessible and effective treatment options for these illnesses through early intervention, aiming to prevent viral entry into cells and accelerate viral clearance.

Red Queen Therapeutics promotes a culture of innovation, collaboration, and scientific rigor. The company is focused on developing novel antiviral therapies that are accessible and effective for a broad range of viral infections, and this mission is reflected in its team of talented scientists and clinicians who are dedicated to advancing groundbreaking research. The company's website highlights the importance of collaboration, both within the company and with external partners, and emphasizes the scientific excellence that drives its work.